Significant improvement of a nevus spilus-type congenital melanocytic nevus with oral selumetinib

Pediatr Dermatol. 2024 Sep-Oct;41(5):936-937. doi: 10.1111/pde.15666. Epub 2024 Jun 17.

Abstract

Giant congenital melanocytic nevi (GCMN) can be cosmetically significant and can lead to melanoma. There is no standard pharmacologic treatment for GCMN. We present the case of an 8-year-old female with kaposiform lymphangiomatosis caused by an NRAS mutation whose nevus spilus-type GCMN improved on oral selumetinib.

Keywords: MEK inhibitor; NRAS; kaposiform lymphangiomatosis; nevus spilus.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Administration, Oral
  • Benzimidazoles* / therapeutic use
  • Child
  • Female
  • GTP Phosphohydrolases / genetics
  • Humans
  • Membrane Proteins / genetics
  • Mutation
  • Nevus, Pigmented* / congenital
  • Nevus, Pigmented* / drug therapy
  • Nevus, Pigmented* / genetics
  • Nevus, Pigmented* / pathology
  • Skin Neoplasms* / congenital
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / genetics
  • Skin Neoplasms* / pathology

Substances

  • Benzimidazoles
  • AZD 6244
  • NRAS protein, human
  • GTP Phosphohydrolases
  • Membrane Proteins

Supplementary concepts

  • Melanocytic nevus syndrome, congenital